{"entity":{"type":"insider","cik":"0001511368","url":"/insider/0001511368","json_url":"/insider/0001511368.json","name":"Hamel Lawrence G","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":5,"n_filings":5,"first":"2017-09-27","last":"2019-03-04","span_basis":"filed_date"},"name_variants":[{"name":"Hamel Lawrence G","source":"filing","n_filings":5,"first_seen":"2017-09-27","last_seen":"2019-03-04"}],"transactions":[{"id":8152457,"accession":"0001209191-19-015617","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-19-015617","line_url":"/filing/0001209191-19-015617#line-1","is_derivative":false,"issuer_cik":"0001427925","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001427925","owner_cik":"0001511368","owner_name":"Hamel Lawrence G","owner_display_name":"Hamel Lawrence G","owner_url":"/insider/0001511368","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3682.0,"shares_display":"3,682","price_per_share":2.81,"price_display":"2.81","price_state":"stated","total_value":10346.42,"total_display":"10,346.42","total_whole":"10,346","shares_owned_after":78053.0,"shares_owned_after_display":"78,053","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-28","filed_date":"2019-03-04","scope":"insider"},{"id":6830314,"accession":"0001209191-18-055127","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-055127","line_url":"/filing/0001209191-18-055127#line-1","is_derivative":false,"issuer_cik":"0001427925","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001427925","owner_cik":"0001511368","owner_name":"Hamel Lawrence G","owner_display_name":"Hamel Lawrence G","owner_url":"/insider/0001511368","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5216.0,"shares_display":"5,216","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":26080.0,"total_display":"26,080.00","total_whole":"26,080","shares_owned_after":29795.0,"shares_owned_after_display":"29,795","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-10-15","filed_date":"2018-10-16","scope":"insider"},{"id":6142386,"accession":"0001209191-18-052334","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-052334","line_url":"/filing/0001209191-18-052334#line-1","is_derivative":false,"issuer_cik":"0001427925","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001427925","owner_cik":"0001511368","owner_name":"Hamel Lawrence G","owner_display_name":"Hamel Lawrence G","owner_url":"/insider/0001511368","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6953.0,"shares_display":"6,953","price_per_share":4.5,"price_display":"4.50","price_state":"stated","total_value":31288.5,"total_display":"31,288.50","total_whole":"31,289","shares_owned_after":35011.0,"shares_owned_after_display":"35,011","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-09-24","filed_date":"2018-09-26","scope":"insider"},{"id":4585219,"accession":"0001437749-17-016704","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001437749-17-016704","line_url":"/filing/0001437749-17-016704#line-1","is_derivative":false,"issuer_cik":"0001427925","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001427925","owner_cik":"0001511368","owner_name":"Hamel Lawrence G","owner_display_name":"Hamel Lawrence G","owner_url":"/insider/0001511368","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10161.0,"shares_display":"10,161","price_per_share":5.29,"price_display":"5.29","price_state":"stated","total_value":53751.69,"total_display":"53,751.69","total_whole":"53,752","shares_owned_after":41964.0,"shares_owned_after_display":"41,964","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-10-02","filed_date":"2017-10-03","scope":"insider"},{"id":4429143,"accession":"0001437749-17-016405","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001437749-17-016405","line_url":"/filing/0001437749-17-016405#line-1","is_derivative":false,"issuer_cik":"0001427925","issuer_name":"ACELRX PHARMACEUTICALS INC","issuer_ticker":"ACRX","issuer_name_source":null,"issuer_url":"/issuer/0001427925","owner_cik":"0001511368","owner_name":"Hamel Lawrence G","owner_display_name":"Hamel Lawrence G","owner_url":"/insider/0001511368","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13827.0,"shares_display":"13,827","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"total_whole":null,"shares_owned_after":68504.0,"shares_owned_after_display":"68,504","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-09-25","filed_date":"2017-09-27","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":5,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":4,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":5},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001427925","name":"ACELRX PHARMACEUTICALS INC","url":"/issuer/0001427925","role":"Officer (Chief Development Officer)","n_filings":5,"first_seen":"2017-09-27","last_seen":"2019-03-04"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001511368","retrieved_at":"2026-08-23T15:14:41+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}